231 related articles for article (PubMed ID: 31743749)
1. Immunological effects of sublingual immunotherapy with Japanese cedar pollen extract in patients with combined Japanese cedar and Japanese cypress pollinosis.
Kikuoka H; Kouzaki H; Matsumoto K; Arai H; Yamamoto S; Tojima I; Shimizu S; Miyashita H; Ogawa Y; Osada T; Okano M; Yuta A; Shimizu T
Clin Immunol; 2020 Jan; 210():108310. PubMed ID: 31743749
[TBL] [Abstract][Full Text] [Related]
2. Identification of Cha o 3 homolog Cry j 4 from Cryptomeria japonica (Japanese cedar) pollen: Limitation of the present Japanese cedar-specific ASIT.
Osada T; Tanaka Y; Yamada A; Sasaki E; Utsugi T
Allergol Int; 2018 Oct; 67(4):467-474. PubMed ID: 29525489
[TBL] [Abstract][Full Text] [Related]
3. Identification of human T cell epitopes in Japanese cypress pollen allergen, Cha o 1, elucidates the intrinsic mechanism of cross-allergenicity between Cha o 1 and Cry j 1, the major allergen of Japanese cedar pollen, at the T cell level.
Sone T; Dairiki K; Morikubo K; Shimizu K; Tsunoo H; Mori T; Kino K
Clin Exp Allergy; 2005 May; 35(5):664-71. PubMed ID: 15898991
[TBL] [Abstract][Full Text] [Related]
4. Recognition of T cell epitopes unique to Cha o 2, the major allergen in Japanese cypress pollen, in allergic patients cross-reactive to Japanese cedar and Japanese cypress pollen.
Sone T; Dairiki K; Morikubo K; Shimizu K; Tsunoo H; Mori T; Kino K
Allergol Int; 2009 Jun; 58(2):237-45. PubMed ID: 19307778
[TBL] [Abstract][Full Text] [Related]
5. Japanese cedar and cypress pollinosis updated: New allergens, cross-reactivity, and treatment.
Osada T; Okano M
Allergol Int; 2021 Jul; 70(3):281-290. PubMed ID: 33962864
[TBL] [Abstract][Full Text] [Related]
6. [Lowered effectiveness of immunotherapy for cypress pollinosis by using Japanese cedar pollen extract].
Horiguchi S; Okamoto Y; Yonekura S; Okawa T; Kunii N; Yamamoto H; Sakurai D; Hanazawa T
Arerugi; 2008 May; 57(5):558-61. PubMed ID: 18520178
[TBL] [Abstract][Full Text] [Related]
7. Cross-reactivity between major IgE core epitopes on Cry j 2 allergen of Japanese cedar pollen and relevant sequences on Cha o 2 allergen of Japanese cypress pollen.
Miyaji K; Okamoto N; Saito A; Yasueda H; Takase Y; Shimakura H; Saito S; Sakaguchi M
Allergol Int; 2016 Jul; 65(3):286-92. PubMed ID: 26916996
[TBL] [Abstract][Full Text] [Related]
8. Long-term sublingual immunotherapy provides better effects for patients with Japanese cedar pollinosis.
Hamada S; Kobayashi Y; Sakamoto D; Shimamura A; Kuroda K; Kawachi R; Kanda A; Asako M; Gotoh M; Okubo K; Tomoda K; Iwai H
Auris Nasus Larynx; 2021 Aug; 48(4):646-652. PubMed ID: 33526319
[TBL] [Abstract][Full Text] [Related]
9. [A MULTICENTER CLINICAL SURVEY ABOUT THE PREVALENCE OF JAPANESE CYPRESS POLLINOSIS AND THE EFFICACY OF SUBLINGUAL IMMUNOTHERAPY WITH JAPANESE CEDAR POLLEN EXTRACT DURING JAPANESE CYPRESS POLLEN DISPERSAL PERIOD].
Oka A; Yuta A; Okawa Y; Masuno S; Tsunoda T; Takahara E; Terada A; Kanai K; Nagakura H; Mimura H; Arao H; Ueyama S; Ueyama A; Tokuda R; Bamba H; Nakazato H; Nakazato M; Amesara R; Nakai S; Araki S; Sakaida M; Tokuriki M; Hama T; Chiba M; Ikeda H; Togawa A; Tsuzuki H; Hyo Y; Niitsu S; Ohkawa C; Nakamoto S; Takeo T; Kumanomidou H; Kanai K; Kitamura H; Sugiura R; Okano M
Arerugi; 2023; 72(9):1138-1146. PubMed ID: 37967960
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis.
Horiguchi S; Okamoto Y; Yonekura S; Okawa T; Yamamoto H; Kunii N; Sakurai D; Fujimura T; Nakazawa K; Yasueda H
Int Arch Allergy Immunol; 2008; 146(1):76-84. PubMed ID: 18087165
[TBL] [Abstract][Full Text] [Related]
11. Cha o 3, a cypress pollen allergen, does not activate basophils in Japanese cypress pollinosis.
Kobayashi Y; Suzuki K; Tateno M; Nakamura Y; Ishimaru K; Nagasaka Y; Sakurai D; Ohashi-Doi K; Nakao A
J Allergy Clin Immunol Glob; 2024 Feb; 3(1):100198. PubMed ID: 38155861
[TBL] [Abstract][Full Text] [Related]
12. Japanese cedar pollen sublingual immunotherapy is effective in treating seasonal allergic rhinitis during the pollen dispersal period for Japanese cedar and Japanese cypress.
Yonekura S; Gotoh M; Okano M; Kurokawa T; Maekawa Y; Okubo K; Okamoto Y
Allergol Int; 2022 Jan; 71(1):140-143. PubMed ID: 34509370
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of a new regimen of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a prospective, randomized, open-label study.
Murakami D; Sawatsubashi M; Kikkawa S; Ejima M; Saito A; Kato A; Komune S
Allergol Int; 2015 Apr; 64(2):161-8. PubMed ID: 25838092
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Fusion Allergens, Cry j 1 and Cry j 2 from Japanese Cedar Pollen, Conjugated with Polyethylene Glycol Potentiate the Attenuation of Cry j 1-Specific IgE Production in Cry j 1-Sensitized Mice and Japanese Cedar Pollen Allergen-Sensitized Monkeys.
Fujimura T; Fujinami K; Ishikawa R; Tateno M; Tahara Y; Okumura Y; Ohta H; Miyazaki H; Taniguchi M
Int Arch Allergy Immunol; 2015; 168(1):32-43. PubMed ID: 26524293
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis.
Okamoto Y; Okubo K; Yonekura S; Hashiguchi K; Goto M; Otsuka T; Murata T; Nakao Y; Kanazawa C; Nagakura H; Okawa T; Nakano K; Hisamitsu M; Kaneko S; Konno A
Int Arch Allergy Immunol; 2015; 166(3):177-88. PubMed ID: 25895909
[TBL] [Abstract][Full Text] [Related]
16. [CLINICAL EFFICACY OF SUBLINGUAL IMMUNOTHERAPY WITH CEDAR POLLEN IN A YEAR OF MASSIVE CEDAR POLLEN DISPERSAL AND ITS EFFECT ON JAPANESE CYPRESS POLLINOSIS].
Yuta A; Ogawa Y; Kozaki H; Shimizu T
Arerugi; 2023; 72(10):1230-1239. PubMed ID: 38092399
[TBL] [Abstract][Full Text] [Related]
17. Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study.
Murakami D; Sawatsubashi M; Kikkawa S; Ejima M; Saito A; Kato A; Komune S
Auris Nasus Larynx; 2016 Feb; 43(1):50-5. PubMed ID: 26197940
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of oral immunotherapy with Cry j1-galactomannan conjugate for Japanese cedar pollinosis.
Murakami D; Kubo K; Sawatsubashi M; Kikkawa S; Ejima M; Saito A; Kato A; Komune S
Auris Nasus Larynx; 2014 Aug; 41(4):350-8. PubMed ID: 24698163
[TBL] [Abstract][Full Text] [Related]
19. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis.
Fujimura T; Yonekura S; Horiguchi S; Taniguchi Y; Saito A; Yasueda H; Inamine A; Nakayama T; Takemori T; Taniguchi M; Sakaguchi M; Okamoto Y
Clin Immunol; 2011 Apr; 139(1):65-74. PubMed ID: 21300571
[TBL] [Abstract][Full Text] [Related]
20. Effects of sublingual immunotherapy with tablets or drops containing Japanese cedar pollen antigens on nasal symptoms and sleep disturbance in patients with Japanese cedar pollinosis.
Fujii T; Kitamura Y; Kamimura S; Takeda N
J Med Invest; 2022; 69(1.2):97-100. PubMed ID: 35466153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
